Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • NHS England’s plan to eliminate Hepatitis C decisively backed by High Court

    NHS England’s plan to eliminate Hepatitis C in England by 2025 is on track after all aspects of a High Court challenge by pharmaceutical company AbbVie were dismissed. The NHS’s single largest medicines procurement, a deal worth almost £1 billion over five years, was launched in April last year but contract start dates had to be delayed by six months after legal action by AbbVie.

    18 January 2019 | NHS England
  • ‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

    There are tens of thousands of immunologic non-responders in the U.S., whose low CD4 numbers put them at much higher risk of heart attacks, stroke, cancers, secondary infections such as tuberculosis, and death. And yet, drug companies and researchers aren’t actively pursuing new treatments that would boost their immunity.

    08 January 2019 | STAT
  • Merck loses bid to revive $200 million Gilead verdict at U.S. high court

    The U.S. Supreme Court on Monday handed a defeat to Merck & Co (MRK.N) by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million (£156.5 million) verdict against rival drugmaker Gilead Sciences Inc (GILD.O) in a dispute involving blockbuster hepatitis C drugs.

    08 January 2019 | Reuters UK
  • Cipla recalls 4,800 bottles of anti-HIV tablets from American market

    Cipla is recalling 4,800 bottles of Nevirapine extended-release tablets used for the treatment of HIV from the American market.

    30 December 2018 | Business Today
  • UK-CAB statement on Brexit, HIV and access to medicines

    On 19 December 2018, the UK-CAB, an HIV treatment advocacy organisation, published recommendations to mimimise the risk for HIV positive people having an interruption in supply of medicines, due to uncertainty over plans for Brexit.

    20 December 2018 | UK-CAB
  • So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

    According to the latest data by Funders Concerned About AIDS (FCAA), such giving decreased by 5 percent, or $37 million, between 2016 and 2017—reaching the lowest level since 2014. A significant portion of the decreases came from the top 20 funders, who accounted for 88 percent of HIV-related philanthropy in 2017.

    19 December 2018 | Inside Philanthropy
  • Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

    GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

    12 December 2018 | BioPharma Dive
  • Bringing Down the House on Intellectual Property and Access

    As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property (IP) protections and the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.

    10 December 2018 | Treatment Action Group
  • Roche Executive Daniel O’Day Is Named Gilead CEO

    The industry veteran will be tasked with helping the drug company revive sales, recover from a disappointing deal

    10 December 2018 | Wall Street Journal
  • Pharmaceutical corporations are failing children with HIV

    One year ago, pharmaceutical corporations committed to improving access to paediatric versions of HIV drugs for children, but very little progress has been made. MSF urges pharmaceutical corporations including Viiv and Merck to immediately register paediatric ARVs and improve access for kids.

    30 November 2018 | Médecins Sans Frontières (MSF)
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.